Commercial Strategy
The Syntopix strategy is to secure intellectual property by focusing on the repositioning of known compounds, or combinations of compounds, that have a history of use in humans. This allows us to uncover previously unknown antimicrobial properties and unexpected beneficial interactions.
Syntopix then seeks to form co-development partnerships with healthcare or pharmaceutical companies who are committed to offering innovative antimicrobial products. The two major routes for commercialisation of the Syntopix technology are:
Joint development
Syntopix forms early stage development partnerships where it
offers knowledge and proprietary methodologies to discover
novel antimicrobial solutions that will differentiate products and
brands; and
Out-licensing
Syntopix seeks to out-licenses its acne formulations,
demonstrated to have phase II clinical efficacy and concepts for
the treatment of infections (including those due to MRSA) to
partners with late stage development and product marketing
expertise.
Recent News
23/08/2010 07:00
AGREEMENT WITH GLOBAL CONSUMER PRODUCTS COMPANY
Syntopix signs an exclusive agreement with a world leading health and personal care brands company.
22/06/2010 07:00
Syntopix welcomes a new board member with Mike Townend joining as Non-executive Director
22/04/2009 13:13
03/02/2010 07:00
Syntopix announces a Directorate change with Tom Bannatyne joining as Chairman.
12/11/2009 07:00
Syntopix announces positive results for its lead dermatological compound SYN0126
